Skip to main content
EXEL
NASDAQ Life Sciences

FDA Extends Zanzalintinib NDA Review by Three Months; New PDUFA Date March 3, 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$57.4
Mkt Cap
$14.23B
52W Low
$33.755
52W High
$59.72
52W Position info
70% above low
Off High info
3.9% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

EXEL sits 70% above its 52-week low of $33.755.

Summary

FDA extended the zanzalintinib NDA review period by three months, moving the PDUFA action date to March 3, 2027, after classifying Exelixis' updated data submission as a major amendment.


Key Events · Product Development and Regulatory · EXEL

  • FDA Extends Zanzalintinib Review

    FDA extended the NDA review period for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months.

  • New PDUFA Date Set

    The updated Prescription Drug User Fee Act action date is March 3, 2027.

  • Major Amendment Classification

    FDA deemed Exelixis' updated safety and efficacy data submission a major amendment, triggering the extension.

  • Pipeline Timing Impact

    The delay pushes back a potential approval decision for zanzalintinib, a key pipeline asset, by approximately three months.


Analysis · EXEL · Life Sciences

The FDA has extended its review of Exelixis' zanzalintinib NDA for metastatic colorectal cancer by three months after deeming the company's updated safety and efficacy data a major amendment. The new PDUFA action date is March 3, 2027. This delays a potential approval decision and pushes back a key pipeline catalyst, though the extension reflects an active information request rather than a rejection. The stock is trading near its 52-week high, so the delay may temper near-term enthusiasm around the zanzalintinib opportunity.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EXEL was trading at $57.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2B. The 52-week trading range was $33.76 to $59.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EXEL - Latest Insights

EXEL
Nov 09, 2026, 7:10 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $71.74
Real-time Price: $68.38 info
Change: -$3.36 (-5%) info
Market Cap: $16.698B info
EXEL
Oct 29, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $66.35
Real-time Price: $68.38 info
Change: +$2.03 (+3%) info
Market Cap: $16.698B info
EXEL
Oct 29, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $66.35
Real-time Price: $68.38 info
Change: +$2.03 (+3%) info
Market Cap: $16.698B info
EXEL
Oct 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $66.34
Real-time Price: $68.38 info
Change: +$2.03 (+3%) info
Market Cap: $16.698B info
EXEL
Aug 31, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $54.64
Real-time Price: $68.38 info
Change: +$13.74 (+25%) info
Market Cap: $16.698B info